[go: up one dir, main page]

DK696988D0 - NUCLEOSIDES AND NUCLEOSIDALALOGS, PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS AND PROCEDURES FOR PREPARING THE COMPOUNDS - Google Patents

NUCLEOSIDES AND NUCLEOSIDALALOGS, PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS AND PROCEDURES FOR PREPARING THE COMPOUNDS

Info

Publication number
DK696988D0
DK696988D0 DK696988A DK696988A DK696988D0 DK 696988 D0 DK696988 D0 DK 696988D0 DK 696988 A DK696988 A DK 696988A DK 696988 A DK696988 A DK 696988A DK 696988 D0 DK696988 D0 DK 696988D0
Authority
DK
Denmark
Prior art keywords
compounds
formula
nucleosidalalogs
nucleosides
procedures
Prior art date
Application number
DK696988A
Other languages
Danish (da)
Other versions
DK696988A (en
DK168443B1 (en
Inventor
Roelf Datema
Zsuzanna Maria Ilona Kovacs
Karl Nils Gunnar Johansson
Bjoern Gunnar Lindborg
Goeran Bertil Stening
Bo Fredrik Oeberg
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of DK696988D0 publication Critical patent/DK696988D0/en
Publication of DK696988A publication Critical patent/DK696988A/en
Application granted granted Critical
Publication of DK168443B1 publication Critical patent/DK168443B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A compound of formula (I), wherein the radicals A, X, R<1>, R<2>, and R<3> are defined as follows: A: formula (a) or formula (b); X: (a) O; (b) S; (c) CH2; R<1>: H; alkyl containing 1-3 carbon atoms; -CH=CH2; -CH=CH-CH3; -CH2-CH=CH2; formula (II); -C=CH; R<2>: H; or R<2> constitutes together with R<3> a carbon-carbon bond; R<3>: H; F; Cl; Br; I; N3; CN; C=CH; OH; OCH3; CH2OH; and when R<3> is F; Cl; Br; I; N3; CN; C=CH; OH; OCH3 or CH2OH it may have either the cis-configuration or trans-configuration relative to the hydroxymethyl function at position 4', or R<3> constitutes together with R<2> a carbon-carbon bond, and therapeutically acceptable salts thereof, for use in therapy, in particular for the treatment of HIV virus infections.
DK696988A 1987-04-16 1988-12-15 Pyrimid-2-on-1-yl compounds, pharmaceutical preparations which comprise these compounds, and a process for preparing the compounds DK168443B1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
SE8701605 1987-04-16
SE8701605A SE8701605D0 (en) 1987-04-16 1987-04-16 NOVEL MEDICINAL COMPOUNDS
SE8800169 1988-04-06
PCT/SE1988/000169 WO1988008001A1 (en) 1987-04-16 1988-04-06 Nucleosides and nucleoside analogues, pharmaceutical composition and processes for the preparation of the compounds
CA000580141A CA1336088C (en) 1987-04-16 1988-10-14 1-(3'-substitued-2', 3'-dideoxy-d-ribofuranosyl) thymine and uracil
CA580141 1988-10-14

Publications (3)

Publication Number Publication Date
DK696988D0 true DK696988D0 (en) 1988-12-15
DK696988A DK696988A (en) 1989-01-31
DK168443B1 DK168443B1 (en) 1994-03-28

Family

ID=25672174

Family Applications (3)

Application Number Title Priority Date Filing Date
DK696988A DK168443B1 (en) 1987-04-16 1988-12-15 Pyrimid-2-on-1-yl compounds, pharmaceutical preparations which comprise these compounds, and a process for preparing the compounds
DK911084A DK108491D0 (en) 1987-04-16 1991-06-07 NUCLEOSIDES AND NUCLEOSIDALALOGS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE RELATIONSHIPS
DK104994A DK104994A (en) 1987-04-16 1994-09-13 Use of Beta-Anomeric Compounds for the Preparation of Pharmaceuticals for the Treatment or Prevention of HIV or Hepatitis B Virus

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK911084A DK108491D0 (en) 1987-04-16 1991-06-07 NUCLEOSIDES AND NUCLEOSIDALALOGS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE RELATIONSHIPS
DK104994A DK104994A (en) 1987-04-16 1994-09-13 Use of Beta-Anomeric Compounds for the Preparation of Pharmaceuticals for the Treatment or Prevention of HIV or Hepatitis B Virus

Country Status (9)

Country Link
JP (1) JPH01503069A (en)
AT (1) ATE115958T1 (en)
AU (1) AU614082B2 (en)
CA (1) CA1336088C (en)
DE (1) DE3852531T2 (en)
DK (3) DK168443B1 (en)
HU (1) HU211547A9 (en)
SE (1) SE8701605D0 (en)
WO (1) WO1988008001A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8629892D0 (en) * 1986-12-15 1987-01-28 Wellcome Found Antiviral compounds
US5631370A (en) 1988-01-20 1997-05-20 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
US4950758A (en) * 1988-01-20 1990-08-21 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
US5175292A (en) * 1988-01-20 1992-12-29 Regents Of The University Of Minnesota Intermediates for the preparation of dideoxycarbocyclic nucleosides
JPH03504492A (en) * 1988-02-24 1991-10-03 エンスティテュ デ ルシェルシェ シミク エ ビョーロジク アプリケ (イ エール セ エ ベ ア) New derivatives of 2'-deoxyuridine substituted in the 5-, 3'-, or 5'-position by an α-aminoacyl group and methods for their production and drugs in which they exist.
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5198539A (en) * 1988-08-19 1993-03-30 Burroughs Wellcome Co. 5'-esters of 2',3'-dideoxy-3'-fluoro-5-ethynyluridine
US5157114A (en) * 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
FI95384C (en) * 1989-04-06 1996-01-25 Squibb Bristol Myers Co Process for the preparation of 3'-deoxy-3'-substituted methyl nucleosides and intermediates used in the process
FR2648045B1 (en) * 1989-06-13 1991-09-27 Centre Nat Rech Scient ALPHA ANOMERIC OLIGONUCLEOTIDE COMPOUNDS INHIBITING REPLICATION OF RETROVIRUSES
NZ234534A (en) * 1989-07-17 1994-12-22 Univ Birmingham Pyrimidine 4'-thionucleoside derivatives and their preparation; intermediates therefor
US5591722A (en) * 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
ATE311399T1 (en) * 1989-09-15 2005-12-15 Southern Res Inst 2'-DEOXY-4'-THIORIBONUCLEOSIDE AS ANTIVIRAL AND ANTICANCER AGENTS
US5827727A (en) * 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
GB9008696D0 (en) * 1990-04-18 1990-06-13 Wellcome Found Anti-viral compounds
US5521163A (en) * 1990-07-13 1996-05-28 University Of Birmingham Antiviral pyrimidine nucleosides and methods for using same
SE9003151D0 (en) * 1990-10-02 1990-10-02 Medivir Ab NUCLEOSIDE DERIVATIVES
US6228860B1 (en) 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
WO1992008717A1 (en) * 1990-11-13 1992-05-29 Biochem Pharma Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US6369066B1 (en) 1990-11-13 2002-04-09 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes with antiviral properties
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
DE637965T1 (en) * 1991-11-26 1995-12-14 Gilead Sciences Inc INCREASED FORMATION OF TRIPLE AND DOUBLE HELICOS FROM OLIGOMERS WITH MODIFIED PYRIMIDINES.
TW393513B (en) * 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
CA2190862A1 (en) * 1994-05-31 1995-12-07 Bo Oberg Post exposure prevention of hiv
US5612319A (en) * 1994-05-31 1997-03-18 Medivir Ab Postexposure prevention of HIV infection or seroconversion
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
AU722214B2 (en) 1995-06-07 2000-07-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis B virus activity
US5869493A (en) 1996-02-16 1999-02-09 Medivir Ab Acyclic nucleoside derivatives
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
EA200700564A1 (en) 1998-02-25 2007-08-31 Эмори Юниверсити 2`-Fluoride
CA2426187C (en) 2000-10-18 2011-08-16 Pharmasset Limited Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
NZ575889A (en) 2006-10-10 2011-09-30 Medivir Ab Hcv nucleoside inhibitor
WO2014109384A1 (en) * 2013-01-10 2014-07-17 塩野義製薬株式会社 Method for producing cross-linked nucleic acid derivative

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD75084A (en) *
US3116282A (en) * 1960-04-27 1963-12-31 Upjohn Co Pyrimidine nucleosides and process
FR2040177A1 (en) * 1969-01-31 1971-01-22 Robugen Gmbh 2-deoxyribosyl-uracil derivs
US3817982A (en) * 1971-12-29 1974-06-18 Syntex Inc 2{40 ,3{40 -unsaturated nucleosides and method of making
DE2918260A1 (en) * 1979-05-07 1980-11-27 Robugen Gmbh 5-alkyl-5'-deoxy-uridine deriVs. use - for normalising cancerous cell functions and accelerating wound healing
US4247544A (en) * 1979-07-02 1981-01-27 The Regents Of The University Of California C-5 Substituted uracil nucleosides
US4267171A (en) * 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
DE2930904A1 (en) * 1979-07-30 1981-02-19 Kailash Kumar Dr Gauri Antitumour use of 5-alkyl-pyrimidine nucleoside derivs. - as potentiators of 5-fluoro-uracil
DE3002197A1 (en) * 1980-01-22 1981-07-23 Robugen Gmbh Pharmazeutische Fabrik Esslingen A.N., 7300 Esslingen 5-Alkyl- and 5-alkenyl-uracil and -cytidine nucleoside derivs. - prepd. e.g. by reaction of 5'-chloro-5'-deoxy cpds. with ammonia
DE3045375A1 (en) * 1980-12-02 1982-07-01 Robugen Gmbh Pharmazeutische Fabrik Esslingen A.N., 7300 Esslingen 5-Substd. pyrimidine nucleoside derivs. - useful as antiviral agents
DE3229169A1 (en) * 1982-08-05 1984-02-09 Robugen GmbH Pharmazeutische Fabrik, 7300 Esslingen Use of 5-alkylpyrimidine nucleosides and their derivatives as cytostatics
ATE135011T1 (en) * 1985-03-16 1996-03-15 Wellcome Found THERAPEUTIC NUCLEOSIDES
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
CY1508A (en) * 1985-03-16 1990-08-03 Wellcome Found Antiviral nucleosides
DK224286A (en) * 1985-05-15 1986-11-16 Wellcome Found 2 ', 3'-dideoxy nucleosides
EP0217580A3 (en) * 1985-09-17 1990-11-07 The Wellcome Foundation Limited Therapeutic nucleosides

Also Published As

Publication number Publication date
CA1336088C (en) 1995-06-27
JPH01503069A (en) 1989-10-19
HU211547A9 (en) 1995-12-28
WO1988008001A1 (en) 1988-10-20
DK108491A (en) 1991-06-07
SE8701605D0 (en) 1987-04-16
DK696988A (en) 1989-01-31
AU614082B2 (en) 1991-08-22
DE3852531D1 (en) 1995-02-02
DK168443B1 (en) 1994-03-28
ATE115958T1 (en) 1995-01-15
AU1689988A (en) 1988-11-04
DE3852531T2 (en) 1995-08-10
DK104994A (en) 1994-09-13
DK108491D0 (en) 1991-06-07

Similar Documents

Publication Publication Date Title
DK696988D0 (en) NUCLEOSIDES AND NUCLEOSIDALALOGS, PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS AND PROCEDURES FOR PREPARING THE COMPOUNDS
DK0565549T3 (en) Use of 1,3-oxathiolannucleoside analogues for the preparation of a preparation for the treatment of hepatitis B
FI894545L (en) THERAPEUTIC NUCLEOSIDES.
ES2133324T3 (en) SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE.
CA2098021A1 (en) Composition Used as a Therapeutic Agent Against Chronic Viral Hepatic Diseases
DK0474712T3 (en) Use of lysolecithin derivatives for the preparation of a pharmaceutical composition
DE3262887D1 (en) 1-beta-d-arabinofuranosyl-(e)-5-(2-halogenovinyl) uracil-5&#39;-phosphate, preparation thereof and use thereof
DK0543000T3 (en) Process for preparing 3-amino-2-chloro-4-alkylpyridines
DK0476066T3 (en) Antiviral preparation containing 3-azido-2,3-dideoxy-5-methylcytidine
IL78954A0 (en) Spiro-imidazolidines and pharmaceutical compositions containing them
DK0430551T3 (en) Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
EP0446921A3 (en) Optically active alkylene-dioxybenzene derivatives and their use in therapy
DE3363376D1 (en) Novel derivatives of guanine
DE68917907D1 (en) Tuftsin analogs and vaccines containing these analogs as adjuvants.
IT1245631B (en) Use of macrolide compounds as anti-inflammatory agents for the treatment of diseases caused by histamine release
ES8308335A1 (en) Antiviral deoxyuridine compounds.
DE69011174D1 (en) Catecholamine ester.
GR1000522B (en) Preparation method of new analogue nucleozites

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed